Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel/Cisplatin Induction vs Consolidation in NSCLC
NCT00271323Phase 2Terminated
- Sponsor
- Sanofi
- Start
- May 2005
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel in non-small cell lung carcinoma (NSCLC) (2 arms), sponsored by Sanofi. Primary endpoints: Safety profile of each treatment group, Overall Response Rate and 2 more. Started May 2005; status: terminated.
02
Drugs
docetaxel
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT00271323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00271323.